IndustryCompany release

Teva Q3 revenue slips 2% as branded drugs grow and FDA approves WELTRUZA

🇺🇸 Teva Pharmaceutical Industries Ltd (TEVA) · Tue 03 Nov 2026

Teva's generic lenalidomide sales fell in the US, but AUSTEDO, AJOVY and UZEDY grew a combined 33% and all three received raised 2026 outlooks.

Teva Pharmaceutical Industries reported results for the quarter ended 30 September 2026 on 3 November. Revenue fell 2%, which the company attributed to weaker US sales of generic lenalidomide.

The decline was offset in part by growth in three branded products. AUSTEDO, AJOVY and UZEDY grew a combined 33% in the quarter, and Teva raised its 2026 outlook for each of them.

On the regulatory front, the US Food and Drug Administration approved WELTRUZA in October 2026. It is a long-acting injectable for schizophrenia. The FDA has also accepted Teva's new drug application for ecopipam in paediatric Tourette syndrome, with an action date in the first quarter of 2027.

Teva also discontinued its study of emrusolmin in multiple system atrophy (MSA) after an interim futility analysis. In general, a futility analysis assesses whether a trial is unlikely to reach its primary objective if it continues. The summary does not give further detail on the result.

What it means for your team

  • Regulatory teams should note the Q1 2027 FDA action date for ecopipam, the next milestone in the paediatric Tourette syndrome filing.
  • The WELTRUZA approval adds a long-acting injectable option in schizophrenia, which market-access teams may need to consider in formulary and payer discussions.
  • Generic lenalidomide pricing and volume pressure in the US was the main drag on Teva's revenue, a trend relevant to generics market-access planning.
  • The emrusolmin MSA study halt after the futility analysis means no near-term development path for that programme in MSA, based on the information available.

Company's press release (SEC filing): Teva Pharmaceutical Industries Ltd ↗

Article written by VigiEye from the official source (Teva Pharmaceutical Industries Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →